(Q33364017)

26 July 2017

title

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer (English)

1 reference

26 July 2017

1 reference

Tally Levy

1

1 reference

26 July 2017

Moshe Inbar

2

1 reference

26 July 2017

Joseph Menczer

3

1 reference

26 July 2017

Dan Grisaru

4

1 reference

26 July 2017

Marek Glezerman

5

1 reference

26 July 2017

Tamar Safra

6

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

95

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

686-690

1 reference

26 July 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.YGYNO.2004.09.005

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_6vjtks4w7zbi5johvhlsjz2sbu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

1 reference

30 July 2022